- Deal gives J&J access to eye drug candidate OLN324
- Blackstone to provide $750 mln for OLN324 late-stage development
- Ollin plans late-stage OLN324 trials this year
Nov 16 (Reuters) - Johnson & Johnson said on Monday it had agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion, expanding its pipeline of eye disease therapies.
Ollin's experimental eye disease treatment, OLN324, will help J&J strengthen its presence in an area where it has a limited footprint, despite its large contact lens business.
OLN324 is being developed to treat diabetic macular edema (DME) and wet age-related macular degeneration (AMD), two leading causes of vision loss. Together, they affect more than 40 million people worldwide, J&J estimated.
"Johnson & Johnson has established strong credentials in ophthalmology with surgical vision equipment and vision care (primarily ACUVUE contact lenses), making this a logical strategic fit," said RBC Capital Markets analyst Trung Huynh.
In a recent early-stage head-to-head study, the drug showed faster and greater improvements in eye structure and greater vision gains in both DME and wet AMD than Roche's Vabysmo, Ollin said.
The buyout includes an upfront $2.2 billion and potential regulatory and commercial milestone payments of up to $1.13 billion, J&J said. It is expected to close by year-end.
Ollin, backed by investment firms ARCH Venture Partners and Mubadala Capital, was established in 2023 to develop treatments for vision-threatening diseases. Its pipeline includes OLN102, currently in preclinical development, for thyroid eye disease and Graves' disease.
The biotech raised $330 million in June to fund late-stage trials of OLN324.
J&J also said it would enter into a separate agreement with Blackstone Life Sciences for a $750 million multi-year funding for the late-stage development of OLN324, in exchange for some payments and royalties.
Last week, Pfizer said Blackstone would provide up to $1.5 billion through 2028 to help fund the development of an experimental monthly obesity treatment.
Reporting by Sneha S K in Bengaluru; Editing by Anil D'Silva and Joyjeet Das
Source: Reuters